| 臺大學術典藏 |
2020-04-10T12:51:02Z |
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
|
Melero I.; Dastani H.B.; Tang H.; Neely J.; El-Khoueiry A.B.;Sangro B.;Yau T.;Crocenzi T.S.;Kudo M.;Chiun Hsu;Kim T.-Y.;Choo S.-P.;Trojan J.;Welling T.H.;3Rd, Meyer T.;Kang Y.-K.;Yeo W.;Chopra A.;Anderson J.;Dela Cruz C.;Lang L.;Neely J.;Tang H.;Dastani H.B.;Melero I.; El-Khoueiry A.B.; Sangro B.; Yau T.; Crocenzi T.S.; Kudo M.; Chiun Hsu; Kim T.-Y.; Choo S.-P.; Trojan J.; Welling T.H.; 3rd, Meyer T.; Kang Y.-K.; Yeo W.; Chopra A.; Anderson J.; dela Cruz C.; Lang L. |
| 臺大學術典藏 |
2020-04-10T12:51:01Z |
Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy
|
Lin Y.-Y.;Tan C.-T.;Chen C.-W.;Ou D.-L.;Cheng A.-L.;Chiun Hsu; Lin Y.-Y.; Tan C.-T.; Chen C.-W.; Ou D.-L.; Cheng A.-L.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-10T12:51:01Z |
Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: Results of the KEYNOTE-028 study
|
Chiun Hsu;Lee S.-H.;Ejadi S.;Even C.;Cohen R.B.;Le Tourneau C.;Mehnert J.M.;Algazi A.;Van Brummelen E.M.J.;Saraf S.;Thanigaimani P.;Cheng J.D.;Hansen A.R.; Chiun Hsu; Lee S.-H.; Ejadi S.; Even C.; Cohen R.B.; Le Tourneau C.; Mehnert J.M.; Algazi A.; Van Brummelen E.M.J.; Saraf S.; Thanigaimani P.; Cheng J.D.; Hansen A.R. |
| 臺大學術典藏 |
2020-04-10T12:51:01Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Hsu C.-H.;Wang M.-J.;Cheng A.-L.;Chiun Hsu; Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-10T12:51:01Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Chen B.-B.;Hsu C.-Y.;Yu C.-W.;Liang P.-C.;Chiun Hsu;Hsu C.-H.;Cheng A.-L.;Shih T.T.-F.; Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; Chiun Hsu; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-04-10T12:51:00Z |
Development of a PD-L1-expressing orthotopic liver cancer model: Implications for immunotherapy for hepatocellular carcinoma
|
Ou D.-L.;Lin Y.-Y.;Hsu C.-L.;Lin Y.-Y.;Chen C.-W.;Yu J.-S.;Miaw S.-C.;Hsu P.-N.;Cheng A.-L.;Chiun Hsu; Ou D.-L.; Lin Y.-Y.; Hsu C.-L.; Lin Y.-Y.; Chen C.-W.; Yu J.-S.; Miaw S.-C.; Hsu P.-N.; Cheng A.-L.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-10T12:51:00Z |
Comparative safety of immune checkpoint inhibitors in cancer: Systematic review and network meta-analysis
|
Xu C.;Chen Y.-P.;Du X.-J.;Liu J.-Q.;Huang C.-L.;Chen L.;Zhou G.-Q.;Li W.-F.;Mao Y.-P.;Chiun Hsu;Liu Q.;Lin A.-H.;Tang L.-L.;Sun Y.;Ma J.; Xu C.; Chen Y.-P.; Du X.-J.; Liu J.-Q.; Huang C.-L.; Chen L.; Zhou G.-Q.; Li W.-F.; Mao Y.-P.; Chiun Hsu; Liu Q.; Lin A.-H.; Tang L.-L.; Sun Y.; Ma J. |
| 臺大學術典藏 |
2020-04-10T12:51:00Z |
Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection
|
Taiwan Cooperative Oncology Group; Chiun Hsu; Pei S.-N.; Chang C.-S.; Chen J.-H.; Yao M.; Lin S.-J.; Lin J.; Yuan Q.; Xia N.; Liu T.-W.; Chen P.-J.; Cheng A.-L.; Tsou H.-H.; Yang H.-C.; Yang H.-C.;Tsou H.-H.;Pei S.-N.;Chang C.-S.;Chen J.-H.;Yao M.;Lin S.-J.;Lin J.;Yuan Q.;Xia N.;Liu T.-W.;Chen P.-J.;Cheng A.-L.;Chiun Hsu;Taiwan Cooperative Oncology Group |
| 臺大學術典藏 |
2020-04-10T12:50:59Z |
Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection
|
Tsou H.-H.;Yang H.-C.;Hsiao C.-F.;Hsiung C.A.;Liu T.-W.;Chuang M.-H.;Wu H.-Y.;Hsu Y.-T.;Tsui C.-W.;Chen P.-J.;Cheng A.-L.;Chiun Hsu;Taiwan Cooperative Oncology Group; Tsou H.-H.; Yang H.-C.; Hsiao C.-F.; Hsiung C.A.; Liu T.-W.; Chuang M.-H.; Wu H.-Y.; Hsu Y.-T.; Tsui C.-W.; Chen P.-J.; Cheng A.-L.; Chiun Hsu; Taiwan Cooperative Oncology Group |
| 臺大學術典藏 |
2020-04-10T12:50:58Z |
Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients
|
Yang S.-H.;Guo J.-C.;Chiun Hsu;Kuo S.-H.;Tien Y.-W.;Cheng A.-L.;Yeh K.-H.; Yang S.-H.; Guo J.-C.; Chiun Hsu; Kuo S.-H.; Tien Y.-W.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2020-04-09T09:32:39Z |
Early alpha‐foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Chih‐Hung Hsu;Ann‐Lii Cheng;Zhong‐Zhe Lin;Yin‐Chung Shen;Li‐Chun Lu;Chiun Hsu;Tsung‐Hao Liu;Yu‐Yun Shao; Yu‐Yun Shao; Tsung‐Hao Liu; Chiun Hsu; Li‐Chun Lu; Yin‐Chung Shen; Zhong‐Zhe Lin; Ann‐Lii Cheng; Chih‐Hung Hsu |
| 臺大學術典藏 |
2020-04-07T08:52:19Z |
Group Report Contest Enhances Problem-Based Learning
|
Chiun Hsu; Shan-Chwen Chang; Fen-Yu Tseng; Jeng-Yi Shieh;Chien-An Yao;Chiun Hsu;Shan-Chwen Chang;Fen-Yu Tseng; JENG-YI SHIEH; Chien-An Yao |
| 臺大學術典藏 |
2020 |
Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study
|
Su Y.-Y.; Chen J.-S.; Shan Y.-S.; Chen L.-T.; Tsou H.-H.; CHIUN HSU; Yen C.-J.; Yang S.-H.; Chen M.-H.; Chiang N.-J. |
| 臺大學術典藏 |
2020 |
A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma�VTCOG T1211 study
|
Shen W.-C.; CHIUN HSU; Lin Y.-L.; Chen J.-S.; Shan Y.-S.; Chen L.-T.; Hsiao H.-H.; Yang S.-H.; Tsai K.K.; Hsiao C.-F.; Chiang N.-J. |
| 臺大學術典藏 |
2020 |
Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial
|
Yau T.; Kang Y.-K.; Kim T.-Y.; El-Khoueiry A.B.; Santoro A.; Sangro B.; Melero I.; Kudo M.; Hou M.-M.; Matilla A.; Tovoli F.; Knox J.J.; Ruth He A.; El-Rayes B.F.; Acosta-Rivera M.; Lim H.-Y.; Neely J.; Shen Y.; Wisniewski T.; Anderson J.; CHIUN HSU |
| 臺大學術典藏 |
2020 |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; CHIUN HSU |
| 臺大學術典藏 |
2019 |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Lu L.-C.; Shen Y.-C.; Chiun Hsu; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.; Liu T.-H.; Shao Y.-Y. |
| 臺大學術典藏 |
2019 |
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
|
Yau T.;Chiun Hsu;Kim T.-Y.;Choo S.-P.;Kang Y.-K.;Hou M.-M.;Numata K.;Yeo W.;Chopra A.;Ikeda M.;Kuromatsu R.;Moriguchi M.;Chao Y.;Zhao H.;Anderson J.;Cruz C.D.;Kudo M.; Yau T.; Chiun Hsu; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Cruz C.D.; Kudo M. |
| 臺大學術典藏 |
2019 |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; CHIUN HSU; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2019 |
Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma
|
Lin Z.-Z.; CHIUN HSU; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; Wu Y.-M.; Hsu H.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2018 |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.;Wang J.-H.;Su C.-W.;Wang T.-E.;Dai C.-Y.;Chen C.-H.;Chen R.-C.;Yang S.-S.;Hung C.-F.;Huang S.-F.;Liao L.-Y.;Huo T.-I.;Wu C.-C.;Lee P.-H.;Ting C.-T.;Lee W.-C.;Chau G.-Y.;Wang C.-C.;Lee K.-T.;Huang Y.-H.;Ho M.-C.;Lin S.-M.;Huang G.-T.;Chen K.-Y.;Lin X.-Z.;Hwang J.-I.;Chiou Y.-Y.;Wang C.-K.;Hu J.-T.;Chen S.-C.;Liang P.-C.;Lee R.-C.;Wu D.-K.;Lin C.-Y.;Lin C.-C.;Cheng A.-L.;Chiun Hsu;Chao Y.;Chen L.-T.;Wang P.-M.;Wang P.-M.;Hong J.-H.;Hsu H.-C.;Chen S.-W.;Leung S.W.;Cheng J.C.-H.;Wu J.-C.;Wu C.-Y.;Hsu Y.-C.;Hsu C.-W.;Ni Y.-H.;Lin C.-L.;Local Ablation Group, Surveillance Group, Diagnosis Group, Staging Group, Surgery Group, Tace/Tare/Hai Group, Target Therapy/Systemic Therapy Group, Radiotherapy Group, Prevention Group, Drafting Group; Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Chiun Hsu; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2017 |
Epithelioid Trophoblastic Tumor Around an Abdominal Cesarean Scar: A Pathologic and Molecular Genetic Analysis
|
Hsiue E.H.-C.; Hsiue E.H.-C.;Chiun Hsu;Tseng L.-H.;Lu T.-P.;Kuo K.-T.; Chiun Hsu; Tseng L.-H.; Lu T.-P.; Kuo K.-T. |
| 臺大學術典藏 |
2017 |
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
|
El-Khoueiry A.B.; Sangro B.; Yau T.; Crocenzi T.S.; Kudo M.; CHIUN HSU; Kim T.-Y.; Choo S.-P.; Trojan J.; Welling T.H.; 3rd, Meyer T.; Kang Y.-K.; Yeo W.; Chopra A.; Anderson J.; dela Cruz C.; Lang L.; Neely J.; Tang H.; Dastani H.B.; Melero I. |
| 臺大學術典藏 |
2017 |
Simultaneous visualization of the subfemtomolar expression of microRNA and microRNA target gene using HILO microscopy
|
Lin Y.-Z.; Ou D.-L.; Chang H.-Y.; Lin W.-Y.; CHIUN HSU; Chang P.-L. |
| 臺大學術典藏 |
2016 |
Tumor heterogeneity in hepatocellular carcinoma: Facing the challenges
|
Lu L.-C.; Hsu C.-H.; CHIUN HSU; Cheng A.-L. |
| 臺大學術典藏 |
2015 |
Gemcitabine plus cisplatin for advanced biliary tract cancer: A systematic review
|
Oh D.-Y.; Chiun Hsu; Chen J.-S.; Chen L.-T.; Orlando M.; Kim J.S.; Lim H.Y.; Park J.O.; Park J.O.;Oh D.-Y.;Chiun Hsu;Chen J.-S.;Chen L.-T.;Orlando M.;Kim J.S.;Lim H.Y. |
| 臺大學術典藏 |
2015 |
Growth arrest dna damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma
|
Cheng A.-L.Ann-Lii; CHIUN HSU; Ou D.-L.; Shyue S.-K.; Lin L.-I.; Feng Z.-R.; Liou J.-Y.; Fan H.-H.; Lee B.-S. |
| 中國醫藥大學 |
2014-06 |
Chemotherapy-Induced Hepatitis B Reactivation in Lymphoma Patients With Resolved HBV Infection: A Prospective Study
|
(Chiun Hsu);(Hsiao-Hui Tsou);(Shyh-Jer Lin);(Ming-Chung Wang);(Ming Yao);(Wen-Li Hwang);(Woei-Yau Kao);邱昌芳(Chang-Fang Chiu);(Sheng-Fung Lin);(Johnson Lin);(Cheng-Shyong Chang);(Hwei-Fang Tien);(Tsang-Wu Liu);(Pei-Jer Chen)*;(Ann-Lii Cheng) |
| 臺大學術典藏 |
2014 |
Hepatitis B and C viruses are not risks for pancreatic adenocarcinoma
|
Chang M.-C.; Chen C.-H.; Liang J.-D.; Tien Y.-W.; Chiun Hsu; Wong J.-M.; Chang Y.-T. |
| 臺大學術典藏 |
2014 |
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: The phase II RACHEL study
|
Ciuleanu T.; Klughammer B.; Meng X.; Csutor Z.; Fittipaldo A.; Zeaiter A.; Lipp R.; Stemmer S.M.; CHIUN HSU; Tham C.K.; Van Cutsem E.; Li C.-P.; Nowara E.; Aprile G.; Moore M.; Federowicz I.; Van Laethem J.-L. |
| 臺大學術典藏 |
2014 |
Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: The role of survivin
|
Ou D.-L.; Lee B.-S.; Lin L.-I.; Liou J.-Y.; Liao S.-C.; CHIUN HSU; Cheng A.-L. |
| 臺大學術典藏 |
2014 |
Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer
|
Cheng A.-L.; Yeh K.-H.; Su W.-C.; Chao Y.; Shen Y.-C.; Li C.-P.; Yen C.-J.; CHIUN HSU; Lin Y.-L.; Lin Z.-Z.; Chen L.-T. |
| 臺大學術典藏 |
2014 |
Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers
|
CHIUN HSU; Chang S.-Y.; Chien S.-F.; Chen Y.-C.; Hu F.-C.; Yang J.C.-H.; Cheng A.-L.; Yeh K.-H.; Chen I.-C.; Kao H.-F. |
| 臺大學術典藏 |
2014 |
Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma
|
Ou D.-L.; Chang C.-J.; Jeng Y.-M.; Lin Y.-J.; Lin Z.-Z.; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; CHIUN HSU; Cheng A.-L. |
| 中國醫藥大學 |
2013-03 |
14-3-3ε overexpression contributes to epithelial-mesenchymal transition of hepatocellular carcinoma
|
(Tzu-An Liu);(Yee-Jee Jan);(Bor-Sheng Ko);(Shu-Man Liang);(Shyh-Chang Chen);(John Wang);(Chiun Hsu);(Yao-Ming Wu);劉俊揚(Jun-Yang Liou)* |
| 臺大學術典藏 |
2013 |
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
|
Shao Y.-Y.; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; CHIUN HSU; Cheng A.-L.; Lin Z.-Z. |
| 臺大學術典藏 |
2013 |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.-H.; Kang Y.K.; Yang T.-S.; Shun C.-T.; Shao Y.-Y.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; CHIUN HSU; Cheng A.-L. |
| 臺大學術典藏 |
2012 |
Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma
|
Shau W.-Y.; Shao Y.-Y.; Yeh Y.-C.; Lin Z.-Z.; Kuo R.; Hsu C.-H.; Chiun Hsu; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2012 |
Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer
|
Lu L.-C.; Shao Y.-Y.; Hsu C.-H.; CHIUN HSU; Cheng W.-F.; Lin Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2012 |
Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma
|
Chen C.-H.; Chang Y.-H.; Chang J.S.; Chen L.-T.; CHIUN HSU; Ch'Ang H.-J. |
| 臺大學術典藏 |
2012 |
Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma
|
Shau W.-Y.; Shao Y.-Y.; Yeh Y.-C.; Lin Z.-Z.; Kuo R.; Hsu C.-H.; CHIUN HSU; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2011 |
Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era
|
Chiun Hsu; Kuo W.H.; Lu Y.S.; Cheng A.L.; Lien H.C.; Chen I.C. ;Lin C.H. ;Huang C.S. ;Lien H.C. ;Chiun Hsu ;Kuo W.H. ;Lu Y.S. ;Cheng A.L.; Chen I.C.; Lin C.H.; Huang C.S. |
| 臺大學術典藏 |
2011 |
Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials
|
Kuo Y.-H.; Tien Y.-W.; CHIUN HSU; Hsu C.-H.; Kuo S.-H.; Cheng A.-L.; Yang S.-H. |
| 臺大學術典藏 |
2011 |
End-of-life care for cancer patients in Taiwan
|
CHIUN HSU |
| 臺大學術典藏 |
2011 |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy
|
Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; CHIUN HSU; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺北醫學大學 |
2010-06 |
Clinical Development and Future Direction for
|
Jacqueline Whang-Peng;Ann-Lii Cheng;Chiun Hsu;Chien-Ming Chen |
| 臺大學術典藏 |
2010 |
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
|
Cheng A.-L.; Kuo W.-H.; Chiun Hsu; Liau J.-Y.; Lee W.-C.; Huang C.-S.; Lu Y.-S.; Hu F.-C.; Kuo K.-T.; Shao Y.-Y.; Shao Y.-Y.;Kuo K.-T.;Hu F.-C.;Lu Y.-S.;Huang C.-S.;Liau J.-Y.;Lee W.-C.;Chiun Hsu;Kuo W.-H.;Chang K.-J.;Lin C.-H.;Cheng A.-L.; Chang K.-J.; Lin C.-H. |
| 臺大學術典藏 |
2010 |
Molecular targeted therapy for advanced hepatocellular carcinoma: Current status and future perspectives
|
Cheng A.-L.; Chiun Hsu; Shen Y.-C.; Shen Y.-C.;Chiun Hsu;Cheng A.-L. |
| 臺大學術典藏 |
2010 |
Eastern asian expert panel opinion: Designing clinical trials of molecular targeted therapy for hepatocellular carcinoma
|
Yeo W.; Chen P.-J.; Furuse J.; Han K.-H.; CHIUN HSU; Lim H.-Y.; Moon H.; Qin S.; Yeoh E.-M.; Ye S.-L. |
| 臺大學術典藏 |
2010 |
Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach
|
Cheng C.-C.; Hu F.-C.; Cheng A.-L.; Chen L.-T.; CHIUN HSU; Shen Y.-C. |
